Motexafin gadolinium | PCI 0120 | CAS#246252-06-2

MedKoo Cat#: 201940 | Name: Motexafin gadolinium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Motexafin gadolinium, also known as PCI 0120, is a synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy.

Chemical Structure

Motexafin gadolinium

CAS#246252-06-2 (gadolinium)

Theoretical Analysis

MedKoo Cat#: 201940

Name: Motexafin gadolinium

CAS#: 246252-06-2 (gadolinium)

Chemical Formula: C52H72GdN5O14

Exact Mass: 0.0000

Molecular Weight: 1148.42

Elemental Analysis: C, 54.39; H, 6.32; Gd, 13.69; N, 6.10; O, 19.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

156436-90-7 (lutetium hydrate) 246252-06-2 (gadolinium) 189752-49-6 (free)

Synonym

PCI 0120; PCI-0120; PCI0120; API-GP 3; Gd texaphyrin; Gd-Texgadolinium; texaphyrin; Gd (III) Texaphryin. US brand name: Xcytrin. Abbreviation: GdTex.

IUPAC/Chemical Name

Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-kappaN1,kappaN18,kappaN23,kappaN24,kappaN25)-, (PB-7-11-233'2'4)-

InChi Key

LAUAZTXAMPOVHP-WRIGXHCHSA-L, VAZLWPAHMORDGR-WRIGXHCHSA-L

InChi Code

InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;;

SMILES Code

CCC1=C(N2[Gd-4]3456(OC(C)=O)OC(C)=O)C=C7[N+]4=C(C=[N+]6C8=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C8[N+]5=CC(C(C)=C9CCCO)=[N+]3C9=CC2=C1CC)C(C)=C7CCCO

Appearance

Solid powder

Purity

>98%

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Phase I trials of Motexafin gadolinium (MTG): Fifteen patients received 37 cycles of treatment, for a median of 2 cycles per patient (range 0-6 cycles). Three patients (20%) completed 6 cycles of therapy. The MTD was identified as MGd, 2 mg/kg/day and doxorubicin, 30 mg/mÂ². Dose limiting toxicities included grade 3 hypertension, pneumonia, bacteremia, and elevated GGT. Serious adverse events also included pulmonary embolism and urinary tract infection requiring hospitalization. There was no exacerbation of cardiac toxicity. No patients attained a response to treatment. Six patients (54%) had stable disease. The median time to disease progression, or to last assessment, was 49 days (range 8-195 days). CONCLUSIONS: The combination of MGd and doxorubicin was fairly well tolerated. However, due to emerging preclinical data suggesting that MGd inhibits ribonucleotide reductase, further development of the combination of MGd plus doxorubicin is not recommended. (source: Invest New Drugs. 2011 Apr;29(2):316-22). (MTG):

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,148.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zheng H, Li P, Ma R, Zhang F, Ji H, Monsky WL, Johnson E, Yang W, Ni C, Gao D, Yang X. Development of a Three-Dimensional Multi-Modal Perfusion-Thermal Electrode System for Complete Tumor Eradication. Cancers (Basel). 2022 Sep 29;14(19):4768. doi: 10.3390/cancers14194768. PMID: 36230690; PMCID: PMC9562205. 2: Osuchowski M, Bartusik-Aebisher D, Osuchowski F, Aebisher D. Photodynamic therapy for prostate cancer - A narrative review. Photodiagnosis Photodyn Ther. 2021 Mar;33:102158. doi: 10.1016/j.pdpdt.2020.102158. Epub 2020 Dec 19. PMID: 33352313. 3: Taguchi YH, Turki T. A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction. PLoS One. 2020 Sep 11;15(9):e0238907. doi: 10.1371/journal.pone.0238907. PMID: 32915876; PMCID: PMC7485840. 4: Wu G, Zhao Z, Yan Y, Zhou Y, Wei J, Chen X, Lin W, Ou C, Li J, Wang X, Xiong K, Zhou J, Xu Z. CPS1 expression and its prognostic significance in lung adenocarcinoma. Ann Transl Med. 2020 Mar;8(6):341. doi: 10.21037/atm.2020.02.146. PMID: 32355785; PMCID: PMC7186668. 5: Thiabaud G, He G, Sen S, Shelton KA, Baze WB, Segura L, Alaniz J, Munoz Macias R, Lyness G, Watts AB, Kim HM, Lee H, Cho MY, Hong KS, Finch R, Siddik ZH, Arambula JF, Sessler JL. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7021-7029. doi: 10.1073/pnas.1914911117. Epub 2020 Mar 16. PMID: 32179677; PMCID: PMC7132275. 6: Kim SJ, Kim HS, Seo YR. Understanding of ROS-Inducing Strategy in Anticancer Therapy. Oxid Med Cell Longev. 2019 Dec 18;2019:5381692. doi: 10.1155/2019/5381692. PMID: 31929855; PMCID: PMC6939418. 7: Baskaran R, Lee J, Yang SG. Clinical development of photodynamic agents and therapeutic applications. Biomater Res. 2018 Sep 26;22:25. doi: 10.1186/s40824-018-0140-z. PMID: 30275968; PMCID: PMC6158913. 8: Gheewala T, Skwor T, Munirathinam G. Photosensitizers in prostate cancer therapy. Oncotarget. 2017 May 2;8(18):30524-30538. doi: 10.18632/oncotarget.15496. PMID: 28430624; PMCID: PMC5444762. 9: Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL. Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angew Chem Int Ed Engl. 2016 Oct 4;55(41):12626-31. doi: 10.1002/anie.201604236. Epub 2016 Jul 5. PMID: 27377046; PMCID: PMC5039070. 10: Herrmann N, Heinz N, Dolg M, Cao X. Quantum chemical study of the autoxidation of ascorbate. J Comput Chem. 2016 Jul;37(20):1914-23. doi: 10.1002/jcc.24408. Epub 2016 Jun 18. PMID: 27316823. 11: Biersack B, Schobert R. Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases. Adv Exp Med Biol. 2016;893:211-224. doi: 10.1007/978-3-319-24223-1_11. PMID: 26667346. 12: Qiu L, Zhang F, Shi Y, Bai Z, Wang J, Li Y, Lee D, Ingraham C, Feng X, Yang X. Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins. Radiology. 2016 May;279(2):400-9. doi: 10.1148/radiol.2015150895. Epub 2015 Nov 24. PMID: 26599802; PMCID: PMC4851136. 13: Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Whittington R, Miles J, Glatstein E, Hahn SM. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy. Proc SPIE Int Soc Opt Eng. 2014 Jun 14;5315:132-142. doi: 10.1117/12.528968. PMID: 26146442; PMCID: PMC4489148. 14: Zhang F, Bai Z, Shi Y, Wang J, Li Y, Yang X. Interventional MRI-guided local delivery of agents into swine bile duct walls using MR-compatible needle- integrated balloon catheter system. NMR Biomed. 2015 Jun;28(6):679-84. doi: 10.1002/nbm.3308. Epub 2015 Apr 22. PMID: 25900480; PMCID: PMC4441522. 15: Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. doi: 10.1016/j.ijrobp.2014.12.050. PMID: 25832688; PMCID: PMC4706375. 16: Zhang DG, Feygelman V, Moros EG, Latifi K, Zhang GG. Monte Carlo study of radiation dose enhancement by gadolinium in megavoltage and high dose rate radiotherapy. PLoS One. 2014 Oct 2;9(10):e109389. doi: 10.1371/journal.pone.0109389. PMID: 25275550; PMCID: PMC4183586. 17: Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol. 2014 Nov 1;92(1):90-101. doi: 10.1016/j.bcp.2014.07.017. Epub 2014 Jul 28. PMID: 25078786. 18: Kelley MS, Shiozaki T. Large-scale Dirac-Fock-Breit method using density fitting and 2-spinor basis functions. J Chem Phys. 2013 May 28;138(20):204113. doi: 10.1063/1.4807612. PMID: 23742460. 19: Meng Y, Wang J, Sun J, Zhang F, Willis P, Li J, Wang H, Zhang T, Soriano S, Qiu B, Yang X. 3.0-T MR imaging of intracoronary local delivery of motexafin gadolinium into coronary artery walls. Radiology. 2013 Aug;268(2):556-62. doi: 10.1148/radiol.13121451. Epub 2013 Mar 19. PMID: 23513243; PMCID: PMC3721057. 20: Wang H, Zhang F, Meng Y, Zhang T, Willis P, Le T, Soriano S, Ray E, Valji K, Zhang G, Yang X. MRI-monitored intra-shunt local agent delivery of motexafin gadolinium: towards improving long-term patency of TIPS. PLoS One. 2013;8(2):e57419. doi: 10.1371/journal.pone.0057419. Epub 2013 Feb 28. PMID: 23468986; PMCID: PMC3585394.